Document is current
Any future updates will be listed below
-
Authors
Simonetti, Fiorenzo
Voll, Felix
Alfonso, Fernando
Gräßer, Christian
Janisch, Marion
Joner, Michael
Kessler, Thorsten
Kuna, Constantin
Leistner, David Manuel
Lenz, Tobias
Presch, Antonia
Rheude, Tobias
Sager, Hendrik
Schunkert, Heribert
Starnecker, Fabian
Wiebe, Jens
Kastrati, Adnan
Cassese, Salvatore https://orcid.org/0000-0002-8668-4313
Xhepa, Erion
-
Funding
Funding for this research was provided by:
Abbott Vascular
Technische Universität München
- License Information
-
More Information
Article History
Received: 9 May 2025
Accepted: 16 June 2025
First Online: 30 June 2025
Declarations
:
: The authors confirm that patient consent forms will be obtained for the enrollment in this study. This trial will be conducted in accordance with the Declaration of Helsinki, ISO 14155, and applicable local laws and regulations. The protocol, amendments, and the subject's informed consent were approved by all participating sites'independent ethics committees (IEC). No animal studies were carried out by the authors for this article.
: Dr.Kuna received speaker fee from AstraZeneca; Dr. Voll received speaking fees from AstraZeneca, Translumina Therapeutics, SIS-Medical and Abbott educational Grants by Abbott, SIS-Medical and Inari Medical. E. Xhepa reports consulting services for Edwards Lifesciences, lecture fees and honoraria from Abbott Vascular, AstraZeneca, Boston Scientific and SIS Medical not related to the current work; proctor fees from Abbott Vascular and financial support for attending meetings and/or travel expenses from Abbott Vascular and SIS Medical. The other authors have nothing to disclose.
